vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). ROGERS CORP runs the higher net margin — 2.2% vs -14.6%, a 16.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 5.2%). ROGERS CORP produced more free cash flow last quarter ($1.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -3.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
AXSM vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $200.5M |
| Net Profit | $-28.6M | $4.5M |
| Gross Margin | — | 32.2% |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 2.2% |
| Revenue YoY | 65.0% | 5.2% |
| Net Profit YoY | 61.9% | 421.4% |
| EPS (diluted) | $-0.55 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $196.0M | $201.5M | ||
| Q3 25 | $171.0M | $216.0M | ||
| Q2 25 | $150.0M | $202.8M | ||
| Q1 25 | $121.5M | $190.5M | ||
| Q4 24 | $118.8M | $192.2M | ||
| Q3 24 | $104.8M | $210.3M | ||
| Q2 24 | $87.2M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-28.6M | $4.6M | ||
| Q3 25 | $-47.2M | $8.6M | ||
| Q2 25 | $-48.0M | $-73.6M | ||
| Q1 25 | $-59.4M | $-1.4M | ||
| Q4 24 | $-74.9M | $-500.0K | ||
| Q3 24 | $-64.6M | $10.7M | ||
| Q2 24 | $-79.3M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 3.5% | ||
| Q3 25 | -27.0% | 7.3% | ||
| Q2 25 | -24.5% | -33.3% | ||
| Q1 25 | -46.9% | -0.2% | ||
| Q4 24 | -61.1% | -6.6% | ||
| Q3 24 | -59.8% | 6.9% | ||
| Q2 24 | -89.5% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -14.6% | 2.3% | ||
| Q3 25 | -27.6% | 4.0% | ||
| Q2 25 | -32.0% | -36.3% | ||
| Q1 25 | -48.9% | -0.7% | ||
| Q4 24 | -63.1% | -0.3% | ||
| Q3 24 | -61.7% | 5.1% | ||
| Q2 24 | -91.0% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.55 | $0.20 | ||
| Q3 25 | $-0.94 | $0.48 | ||
| Q2 25 | $-0.97 | $-4.00 | ||
| Q1 25 | $-1.22 | $-0.08 | ||
| Q4 24 | $-1.54 | $-0.04 | ||
| Q3 24 | $-1.34 | $0.58 | ||
| Q2 24 | $-1.67 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.2B |
| Total Assets | $689.8M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $322.9M | $197.0M | ||
| Q3 25 | $325.3M | $167.8M | ||
| Q2 25 | $303.0M | $157.2M | ||
| Q1 25 | $300.9M | $175.6M | ||
| Q4 24 | $315.4M | $159.8M | ||
| Q3 24 | $327.3M | $146.4M | ||
| Q2 24 | $315.7M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.3B | ||
| Q4 24 | $57.0M | $1.3B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $689.8M | $1.4B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.5B | ||
| Q4 24 | $568.5M | $1.5B | ||
| Q3 24 | $561.5M | $1.5B | ||
| Q2 24 | $548.2M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $5.8M |
| Free Cash FlowOCF − Capex | $-18.7M | $1.1M |
| FCF MarginFCF / Revenue | -9.6% | 0.5% |
| Capex IntensityCapex / Revenue | 0.0% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-18.7M | $46.9M | ||
| Q3 25 | $1.0M | $28.9M | ||
| Q2 25 | $-32.4M | $13.7M | ||
| Q1 25 | $-43.4M | $11.7M | ||
| Q4 24 | $-26.2M | $33.7M | ||
| Q3 24 | $-18.6M | $42.4M | ||
| Q2 24 | $-30.1M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-18.7M | $42.2M | ||
| Q3 25 | $988.0K | $21.2M | ||
| Q2 25 | $-32.4M | $5.6M | ||
| Q1 25 | $-43.7M | $2.1M | ||
| Q4 24 | $-26.2M | $18.3M | ||
| Q3 24 | $-18.7M | $25.2M | ||
| Q2 24 | $-30.2M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -9.6% | 20.9% | ||
| Q3 25 | 0.6% | 9.8% | ||
| Q2 25 | -21.6% | 2.8% | ||
| Q1 25 | -36.0% | 1.1% | ||
| Q4 24 | -22.1% | 9.5% | ||
| Q3 24 | -17.9% | 12.0% | ||
| Q2 24 | -34.6% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.3% | 5.0% | ||
| Q4 24 | 0.0% | 8.0% | ||
| Q3 24 | 0.1% | 8.2% | ||
| Q2 24 | 0.1% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
